Solid biosciences receives fda fast track designation for sgt-212 dual route of administration gene therapy for friedreich's ataxia

- only dual route gene transfer therapy in development to treat friedreich's ataxia with fda ind clearance and fast track designation -

SLDB Ratings Summary

SLDB Quant Ranking